Connect Biopharma Holdings Limited
CNTB
Rank in Stocks
#23442
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Share Price
$0.6653
Last synced: 2026-11-12
Market Cap
$41.84M
Change (1 day)
-3.43%
Change (1 year)
-60.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Connect Biopharma Holdings Limited (CNTB)
Category
Healthcare
EPS for Connect Biopharma Holdings Limited (CNTB)
EPS as of June 2026 TTM: $-0.88
According to Connect Biopharma Holdings Limited's latest financial reports, its current EPS (TTM) is $-0.88. At the end of 2025 the company had an EPS of $-1.00, a decrease compared to its 2024 EPS of $-0.28.
EPS history for Connect Biopharma Holdings Limited from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.88 | -12.00% |
| 2025 | $-1.00 | 257.14% |
| 2024 | $-0.28 | -74.07% |
| 2023 | $-1.08 | -92.55% |
| 2022 | $-14.50 | -42.00% |
| 2021 | $-25.00 | 73.01% |
| 2020 | $-14.45 | 378.48% |
| 2019 | $-3.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,879.55% |
US
|
|
| $-7.07 | 703.41% |
US
|
|
| $-5.29 | 501.14% |
AU
|
|
| $12.88 | -1,563.65% |
BE
|
|
| $21.56 | -2,550.00% |
NL
|
Questions about Connect Biopharma Holdings Limited's earnings per share (EPS)
What is Connect Biopharma Holdings Limited's earnings per share (EPS)?
Connect Biopharma Holdings Limited's earnings per share (EPS) over the last twelve months is $-0.88, as of Jun 2026.
What was Connect Biopharma Holdings Limited's earnings per share (EPS) in 2025?
In 2025, Connect Biopharma Holdings Limited's earnings per share (EPS) was $-1.00, compared with $-0.28 in 2024.
How has Connect Biopharma Holdings Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Connect Biopharma Holdings Limited's earnings per share (EPS) was highest in 2024 ($-0.28) and lowest in 2021 ($-25.00).
How does Connect Biopharma Holdings Limited's earnings per share (EPS) compare with similar companies?
Connect Biopharma Holdings Limited's earnings per share (EPS) ($-0.88) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.